Expert Interview
Analyzing the PARADIGM Phase 3 Trial Results of Solriamfetol in Major Depressive Disorder with and without Excessive Daytime Sleepiness from Axsome Therapeutics
Ticker(s): AXSMA psychiatrist or clinical researcher with extensive experience in mood disorders, specifically Major Depressive Disorder. The expert should have a background in conducting clinical trials, an understanding of sleep-related symptoms in psychiatric conditions, and familiarity with the pharmacological mechanisms of dopamine and norepinephrine reuptake inhibitors.
The PARADIGM trial did not achieve a statistically significant change in the overall MDD population but showed clinically meaningful improvements in patients with severe EDS. What factors might contribute to this differential efficacy between these subgroups?
Added By: slingshot_insightsGiven that approximately 50% of MDD patients experience EDS, how does this symptom impact the overall disease burden and treatment outcomes in MDD?
Added By: slingshot_insightsSolriamfetol is known as a dopamine and norepinephrine reuptake inhibitor. How might its pharmacological profile explain the observed benefits in MDD patients with severe EDS?
Added By: slingshot_insightsThe results suggest potential benefits for a specific subset of MDD patients. How might these findings influence the move toward more personalized treatment approaches in depression?
Added By: slingshot_insightsThe trial reported that solriamfetol was well tolerated with a safety profile consistent with previous studies. How important is this consistency when considering new therapeutic options for MDD?
Added By: slingshot_insightsAxsome plans to initiate a Phase 3 trial focusing on MDD patients with EDS. What key aspects should this future study address to build upon the PARADIGM trial findings?
Added By: slingshot_insightsConsidering the mixed results, what challenges might Axsome face in seeking regulatory approval for solriamfetol as a treatment for MDD with EDS?
Added By: slingshot_insightsHow do these findings contribute to the current understanding and treatment paradigm of MDD, especially concerning patients presenting with EDS?
Added By: slingshot_insightsAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
